ArticleCancer medicine2026
Insurance Network Status and 1-Year Health Care Utilization and Outpatient Costs Among Commercially Insured Patients With Newly Diagnosed and Non-Definitively Treated Prostate Cancer, 2010-2021.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionCancer care in the U.S. exceeds $200B, with patients paying over $16B out-of-pocket. We examined whether insurance network status (in-network [IN] vs. out-of-network [OON]) at prostate cancer diagnosis was associated with subsequent OON care use and patient spending within 1 year of diagnosis.
methodsUsing the MarketScan database (2010-2021), we identified patients aged 40-64 with a new outpatient prostate cancer diagnosis. Patients who received definitive local treatment (radical prostatectomy or radiotherapy) were excluded. The exposure was network status at diagnosis. Outcomes were the proportion of OON claims and patient spending for prostate cancer-related care and/or non-definitive treatments during 1 year of follow-up. Results were stratified by insurance type.
resultsAmong 67,271 patients, 5% were diagnosed OON. Compared with IN diagnosis, OON diagnosis was associated with greater OON follow-up claims (aIRR 29.0, 95% CI 25.0, 33.5), lower odds of prostate cancer-related spending (aOR 0.55, 95% CI 0.49, 0.61), and lower outpatient costs (% difference = -8.6, 95% CI -13.4, -3.6). In stratified analyses, patients with HMO (aOR 0.54, 95% CI 0.44, 0.67) and PPO (aOR 0.47, 95% CI 0.41, 0.54) plans had lower odds of any spending. Patients with HMO (% difference = -22.3, 95% CI -30.9, -12.5) and CDHP (% difference = -26.5, 95% CI -43.6, -4.3) plans had lower costs.
conclusionsOON diagnosis was associated with continued OON care. Some patients diagnosed OON had lower liability, likely reflecting differences in plan design and adjudicated claims. Claims-based estimates may underestimate the financial impact of OON non-definitive prostate cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.